Skip to main content
. 2018 Jul 7;24(10):2093–2103. doi: 10.1093/ibd/izy222

TABLE 1:

Overall Sample Characteristics

No Chronic Opioid Therapy (n = 76,584) Chronic Opioid Therapy (n = 17,084) P
Sex, No. (%)
 Female 38,548 (50.3) 10,134 (59.3) <0.001
Age
 Mean (median), y 23.0 (23) 23.6 (24) <0.001
  15–19 y, No. (%) 18,512 (24.2) 3267 (19.1) <0.001
  20–24 y, No. (%) 26,505 (34.6) 5710 (33.4)
  25–29 y, No. (%) 31,567 (41.2) 8107 (47.5)
Geographic region, No. (%)
 Northeast 18,148 (23.7) 2833 (16.6) <0.001
 North Central 18,910 (24.7) 4087 (23.9)
 South 27,151 (35.5) 7076 (41.4)
 West 10,805 (14.1) 2800 (16.4)
 Other 1570 (2.1) 288 (1.7)
Insurance,a No. (%)
 EPO/PPO 49,299 (69.3) 10,934 (68.1) <0.001
 HMO/Cap POSb 9915 (13.9) 2437 (15.2)
 HDHP/CDHP 5915 (8.3) 1123 (8.3)
 POS 5040 (7.1) 1331 (7.0)
 COMP 954 (1.3) 234 (1.5)
IBD type, No. (%)
 Crohn’s disease 38,860 (50.7) 10,039 (58.8) <0.001
 Ulcerative colitis 31,884 (41.6) 5546 (32.5)
 Indeterminate colitis 5840 (7.6) 1499 (8.8)
IBD medications, No. (%)
 Biologics 20,069 (26.2) 6292 (36.8) <0.001
 Corticosteroids 35,301 (46.1) 12,838 (75.2) <0.001
 Immunomodulators 21,955 (28.7) 5789 (33.9) <0.001
 5-ASA 44,020 (57.5) 9910 (58) 0.21
Comorbidities, %
Pain
 Abdominal pain 56 85.5 <0.001
 Joint pain 21 46.4 <0.001
 Chronic back pain 6.3 22.9 <0.001
 Migraines 6.3 19 <0.001
 Chronic pain, unspecified 1.2 14.2 <0.001
 Osteoarthritis 1.5 6.2 <0.001
 Rheumatoid arthritis 1.3 3.8 <0.001
Psychiatric
 Depression 22.2 55.2 <0.001
 Anxiety 14.2 35.1 <0.001
Substance use
 Tobacco 5.7 22.4 <0.001
 Substance abuse 1.6 8.7 <0.001
 Alcohol abuse 1.9 5.6 <0.001

aPatients were classified under the insurance plan of their first UC or CD diagnosis.

bHMO/Cap POS are capitated plans. All other plans are noncapitated.